Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Current Research on Biosciences and Biotechnology

ERCC2 rs13181 and ERCC1 rs11615 polymorphisms in non-small cell lung cancer patients in West Java: towards personalized medicine approaches Afifah, Nadiya Nurul; Effendi, M. Fariz; Diantini, Ajeng; Barliana, Melisa Intan; Intania, Ruri
Current Research on Biosciences and Biotechnology Vol. 6 No. 2 (2025)
Publisher : Institut Teknologi Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/crbb.2025.6.2/3DCBQ451

Abstract

Non-Small Cell Lung Cancer (NSCLC) is a disease with a high incidence rate, low survival due to late diagnosis and treatment delays, and varying effectiveness of platinum-based chemotherapy. Individual responses to platinum-based chemotherapy are influenced by genetic polymorphisms in genes affecting pharmacokinetic and pharmacodynamic mechanisms. This study focuses on identifying polymorphisms in the ERCC2 and ERCC1 genes, which play a role in platinum pharmacodynamics, and their effects on chemotherapy response. The study involved 23 NSCLC patients conducted at Dr. H.A. Rotinsulu Lung Hospital in Bandung. Polymorphism data were obtained through genotype analysis using sequencing methods from prospective whole blood samples of patients, while chemotherapy effectiveness was assessed by evaluating chemotherapy response using the RECIST 1.1 method, and radiological response prediction and prognostic factors were determined through CYFRA 21-1 levels. The results showed an OR of 0.964 (95% CI: 0.160 - 5.795) for ERCC2 rs13181 CC + AC vs. AA against chemotherapy response evaluation by RECIST 1.1, and 0.722 (95% CI: 0.062 - 8.464) against CYFRA 21-1 values. Meanwhile, for ERCC1 rs11615, an OR of 0.268 (95% CI: 0.046 - 1.548) CT + TT vs. CC for RECIST 1.1 and 0.3 (95% CI: 0.026 - 3.427) for CYFRA 21-1 values were obtained. In clinical interpretation, it is known that variant alleles at rs13181 and rs11615 have potential for better chemotherapy response although not statistically significant (p>0.05), these results can be considered when assessing patient response to chemotherapy within six cycles. This study provides initial data and forms the basis for future comprehensive cohort observational research.
Co-Authors Abdurahman Ridho Afifah, Nadya Nurul AGATHA VIKA PURWANINGTYAS Ahmad Faried Ahmad Muhtadi Ajeng Diantini, Ajeng Aliya Nur Hasanah Among, Sayyid Andi Wijaya Andi Wijaya ANDI WIJAYA Angliana Chouw, Angliana Anna Meiliana Anna Meiliana ARNANDA, QUINZHEILLA PUTRI Balqist, Syara Nur Fitri Bonor, Toga Chandra Agung Purnama Cissy Bana Kartasasmita Cynthia Retna Sartika, Cynthia Retna Dedi Suyatno Dewi Muliaty Didi Susanto Driyanti Rahayu Edhyana Sahiratmadja Effendi, M. Fariz ELLENA MAGGYVIN Erizal Sugiono Eva Feriadi Fajar, Desi Reski Febio Gutama Febriyanti, Maya Haifa, Rima HISBAN HAMID ARIFKI Ida Paulina Sormin Imas Maesaroh Indradi, Raden Bayu Intania, Ruri Irma Melyani Puspitasari Irma Rahayu Latarissa Irmansyah Irmansyah Ivan Pradipta Ivan Surya Pradipta Karina Erlianti Kennardi, Gabriel Bagus Keri Lestari Khaira, Syifa Komang Suma Triyasa Laniyati Hamijoyo, Laniyati LILY CYNTIA FAUZI Luki Yogaswara Yusuf Made Putra Semadhi Maisyarah, Intan Timur Maya Febriyanti Miftakh Nur Rahman Miswar Fattah Moses Prasetio Muhaimin Muhaimin Muhammad Fauzi Munir Alinu Mulki Mustikawati, Bunga Nadiya Nurul Afifah Nuning Nurcayani Peratiwi, Shafira Galuh Permatasari, Lany Indah Pratama, Muhammad Syawal Prayudi Santoso Putri Maharani Putri, Nazwa Septiriana Qolbina, Shofura Marsa Raden Maya Febriyanti Rendrayani, Farida Rimadani Pratiwi Rizki Rahmadi Pratama Rizky Abdulah Sahila, Elma N. M. R. Sartika Aprianti Shelly Iskandar Soemarie, Yulistia Budianti Syahrina, Nadira Alvi Tahara, Nabila Theresia Ratnadevi TIANA MILANDA Tina Rostinawati Widya Naftalia Wijasa Yudisia Ausi Yulistia Budianti Soemarie Yulistia Budianti Soemarie Yuni Elsa Hadisaputri Zakiyah, Neily Zelika Mega Ramadhania